Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.117047 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Nethanel Asher und 14 weiteren Autor:innen. Beteiligte Einrichtung: Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. Electronic address: netanelash1@clalit.org.il. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Melanoma. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
BACKGROUND: Nivolumab-relatlimab, a dual immune checkpoint inhibitor targeting PD-1 and LAG-3, has demonstrated improved outcomes compared with nivolumab monotherapy in previously untreated advanced melanoma. However, real-world data in broader and less selected populations remain limited. METHODS: We conducted a multicenter retrospective study across 10 oncology centers in Israel, including adults with unresectable or metastatic melanoma treated with first-line nivolumab-relatlimab. Endpoints included overall survival (OS), progression-free survival (PFS), melanoma-specific survival (MSS), objective response rate (ORR), and safety. Predictors of outcomes were explored using multivariable analyses. RESULTS: A total of 117 patients were included. The cohort was older and clinically frailer than those enrolled in pivotal trials (median age 75 years; 38% aged ≥80 years). The ORR was 69.8%, including a complete response rate of 43.6%. Median PFS was 18.6 months, while median OS and MSS were not reached; 12-month OS was 74.1%. Grade 3-4 adverse events occurred in 11% of patients, and treatment discontinuation due to toxicity in 14.5%, predominantly among patients aged ≥80 years. In multivariable analyses, liver and/or bone metastases and prior neo- or adjuvant therapy were associated with inferior outcomes. A higher-than-anticipated rate of neurologic toxicity was observed. CONCLUSIONS: In routine clinical practice, nivolumab-relatlimab demonstrated high response rates and durable disease control despite an older and frailer population than in clinical trials. These findings support its use as a frontline option while identifying subgroups with poorer outcomes who may benefit from alternative strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. Electronic address: netanelash1@clalit.org.il.
- Center for Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; Department of Clinical Microbiology and Immunology, Gray Faculty of Medical and Health Sciences, Tel Aviv University, T…
- Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
- Fishman Oncology Center, Rambam Health Care Campus, Haifa, Israel.
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Asher, N., Avner, M., Goldberg, N., Markel, G., Israei-Weller, N., Dokhan, R., Lev-Ari, S., Grynberg, S., Bar-Sela, G., Wainstein, E., Yakobson, A., Miodovnik, M., Kozlener, E., Rasco, A. F., & Lotem, M. (2026). Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117047
Vancouver
Asher N, Avner M, Goldberg N, Markel G, Israei-Weller N, Dokhan R, et al. Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117047
BibTeX
@article{Asher2026,
author = {Asher, Nethanel and Avner, Moti and Goldberg, Nadav and Markel, Gal and Israei-Weller, Noa and Dokhan, Rami and Lev-Ari, Shaked and Grynberg, Shirly and Bar-Sela, Gil and Wainstein, Ehud and Yakobson, Alexander and Miodovnik, Mor and Kozlener, Ela and Rasco, Adi F and Lotem, Michal},
title = {Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.117047}
}
EUVIMED